ArticleActa neuropathologica communications2023
Retina-to-brain spreading of α-synuclein after intravitreal injection of preformed fibrils.
Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Retinal Architecture in Parkinson's Disease with Rapid Eye Movement Sleep Behaviour Disorder: Insights from a Scoping Review.Annals of neurosciences · 2026Review
- Retinal Pathology and Synucleinopathy in the Visual Pathway of α-Synuclein Preformed Fibril Mouse Model of Parkinson's Disease.Brain and behavior · 2026Article
- Retinal alterations resemble brain pathology in a rat model of Parkinson's disease induced by intranigral infusion of α-synuclein oligomers.Cell death discovery · 2025Article
- A Narrative Review on Biochemical Markers and Emerging Treatments in Prodromal Synucleinopathies.Clinics and practice · 2025Review
- Review
- Correction: Retina-to-brain spreading of α-synuclein after intravitreal injection of preformed fibrils.Acta neuropathologica communications · 2024Article
- A new perspective on positive symptoms: expression of damage or self-defence mechanism of the brain?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- A topographical atlas of α-synuclein dosage and cell type-specific expression in adult mouse brain and peripheral organs.NPJ Parkinson's disease · 2024Article
- Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease.International journal of molecular sciences · 2024Review
- Retinal ganglion cell type-specific expression of synuclein family members revealed by scRNA-sequencing.International journal of medical sciences · 2024Article
- α-Synuclein propagation leads to synaptic abnormalities in the cortex through microglial synapse phagocytosis.Molecular brain · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the aggregation of misfolded α-synuclein and progressive spreading of the aggregates from a few discrete regions to wider brain regions. Although PD has been classically considered a movement disorder, a large body of clinical evidence has revealed the progressive occurrence of non-motor symptoms. Patients present visual symptoms in the initial stages of the disease, and accumulation of phospho-α-synuclein, dopaminergic neuronal loss, and retinal thinning has been observed in the retinas of PD patients. Based on such human data, we hypothesized that α-synuclein aggregation can initiate in the retina and spread to the brain through the visual pathway. Here, we demonstrate accumulation of α-synuclein in the retinas and brains of naive mice after intravitreal injection of α-synuclein preformed fibrils (PFFs). Histological analyses showed deposition of phospho-α-synuclein inclusions within the retina 2 months after injection, with increased oxidative stress leading to loss of retinal ganglion cells and dopaminergic dysfunction. In addition, we found accumulation of phospho-α-synuclein in cortical areas with accompanying neuroinflammation after 5 months. Collectively, our findings suggest that retinal synucleinopathy lesions initiated by intravitreal injection of α-synuclein PFFs spread to various brain regions through the visual pathway in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.